Prevention Archives – Page 2 of 3 – Treatment Action Group

The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation

September 21, 2022
Dorrit Walsh

As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.

The Right to Prevent TB

March 17, 2022
Dorrit Walsh

It’s now easier than ever to prevent TB before it develops into active disease or spreads within communities.

New HIV Prevention Research Fact Sheet

October 26, 2021
Dorrit Walsh

HIV prevention research continues to rapidly evolve. The availability of pre-exposure prophylaxis (PrEP) has necessitated the development of new approaches to testing the efficacy of additional biomedical HIV prevention options. This handout was developed in collaboration with the Black AIDS…

Broadly Neutralizing Antibodies for HIV Prevention Fact Sheet

October 26, 2021
Dorrit Walsh

HIV-specific broadly neutralizing antibodies (bNAbs) could have a role in treating, preventing, or even curing HIV. Some HIV-specific bNAbs are already being tested in clinical trials, both for prevention and treatment. This handout was developed in collaboration with the Black…

What’s on the Horizon for Long-Acting Pre-Exposure Prophylaxis (PrEP)? Fact Sheet

October 26, 2021
Dorrit Walsh

Long-acting pre-exposure prophylaxis (PrEP) will be a groundbreaking HIV prevention tool. The approach provides an option to receive intermittent doses of PrEP instead of taking daily pills. This handout provides an update on the development of long-acting PrEP and future…

Treatment Action Group Statement on Early Findings from HPTN 084

November 12, 2020
Dorrit Walsh

Treatment Action Group welcomes the announcement that the phase 3 HPTN 084 trial proved that intramuscular injections of ViiV’s long acting cabotegravir (CAB-LA) every eight weeks were superior to daily oral TDF/FTC pre-exposure prophylaxis (PrEP) in preventing new HIV infections in cisgender women in sub-Saharan Africa.

Global Health and Human Rights Organizations Say U.S. Withdrawal from WHO Is Reckless Act That Could Delay Americans’ Access to COVID-19 Solutions and Prolong Global Pandemic

July 7, 2020
Dorrit Walsh

AVAC, Health GAP and the Treatment Action Group (TAG) strongly condemn the Trump Administration’s withdrawal from the World Health Organization (WHO).

TAG Statement on WHO Updated TB Preventive Therapy Guidance

March 31, 2020
Dorrit Walsh

Last week, Treatment Action Group was pleased to receive the World Health Organization’s (WHO) update to its guidance on TB preventive therapy (TPT).

The Future of Biomedical HIV Prevention Trials: Researcher Viewpoints and Community Survey

March 6, 2020
Dorrit Walsh

This report aims to make more accessible to community advocates discussions around ethical conduct of biomedical prevention trials in the era of PrEP. In early 2019, TAG, along with Black AIDS Institute and the HIV Vaccine Trials Network developed an…

Statement from the ACT NOW:END AIDS Coalition on President Trump’s State of the Union Commitment to Eradicate AIDS

February 5, 2020
Dorrit Walsh

The ACT NOW:END AIDS Coalition, of which TAG is a founding member, released this statement today calling for the administration’s efforts to end the HIV epidemic to be rooted in fact, science, and sensible policies that are consistent with the stated goal of ending HIV.